Improvements in Patient‐Reported Outcomes Through Six Months of Guselkumab Treatment in Patients With Active Psoriatic Arthritis: Real‐World Data From the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry

Objective Evaluate patient‐reported outcomes after 6 months of on‐label guselkumab use in patients with rheumatologist‐diagnosed active psoriatic arthritis (PsA) enrolled in the CorEvitas PsA/Spondyloarthritis Registry. Methods This analysis includes registry participants who initiated and persisted...

Бүрэн тодорхойлолт

Номзүйн дэлгэрэнгүй

Үндсэн зохиолчид:	Philip J. Mease, Alexis Ogdie, John Tesser, Natalie J. Shiff, Ruizhi Sophia Zhao, Soumya D. Chakravarty, Michael Kelleman, Rhiannon Dodge, Robert R. McLean, Aaron Broadwell, Arthur Kavanaugh, Joseph F. Merola
Формат:	Artigo
Хэл сонгох:	Inglês
Хэвлэсэн:	Wiley 2024-05-01
Цуврал:	ACR Open Rheumatology
Онлайн хандалт:	https://doi.org/10.1002/acr2.11657
Шошгууд:	Шошго нэмэх Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!